News Focus
News Focus
icon url

pcrutch

01/30/14 2:01 AM

#173416 RE: jq1234 #173415

Seriously? Yikes. Still not sure what they see in the RA program. Why are they afraid to stick with CF and inlicense some other orphans?
icon url

jq1234

05/01/14 8:43 PM

#177476 RE: jq1234 #173415

VRTX no longer invest in HCV R&D!

[Applause]

Vertex today announced that it has amended the terms of its agreement with Alios BioPharma regarding the development and commercialization of the nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Based on the revised agreement and the rapid changes in the hepatitis C treatment landscape following the introduction of new oral therapies, Vertex plans to out-license VX-135 and to end further investment into research and development efforts in hepatitis C.



1Q2014 Result PR:

http://investors.vrtx.com/releasedetail.cfm?ReleaseID=844664
icon url

DewDiligence

05/01/14 10:07 PM

#177480 RE: jq1234 #173415

VRTX—You and other posters on this board called this some time ago. No discussion required!